Dr Thomas Bachelot is careful to set reasonable expectations for his patients with HR+/HER2–metastatic breast cancer regarding how long their treatment will last and how it will impact them.
Video Categories: Breast Cancer and ESMO
Hope Rugo, MD, discusses common presenting symptoms of HR+/HER2-Â metastatic breast cancer, citing bone metastasis as the most prevalent.
Video Categories: Breast Cancer and ESMO
Sunil Verma, MD, MSEd, FRCPC discusses new classes of therapies for HR+ Breast Cancer.
Video Categories: Breast Cancer and ESMOSunil Verma, MD, MSEd, FRCPC discusses treatment options for this type of cancer.
Video Categories: Breast Cancer and ESMOSunil Verma, MD, MSEd, FRCPC takes up the topic of communicating with patients about what they want for their care.
Video Categories: Breast Cancer and ESMOSunil Verma, MD, MSEd, FRCPC discusses all the patient factors when managing patients who relapse.
Video Categories: Breast Cancer and ESMODr Thomas Bachelot discusses the potential for incorporating immunotherapy into the treatment of patients with hormone receptor–positive diseases but notes that the current data are weak, and further studies are needed to get a better sense of the viability of this treatment option.
Video Categories: Breast Cancer and ESMO
Dr Sibylle Loibl explains how fulvestrant (with or without palbociclib) fits in the treatment paradigm for patients with HR+/ HER2-negative metastatic breast cancer.
Video Categories: Breast Cancer and ESMODr Hope Rugo discusses some of the choices and challenges she’s faced with in treating patients with HR+/ HER2-negative metastatic breast cancer with the goal of helping patients live as long as possible and with the best quality of life.
Video Categories: Breast Cancer and ESMODr Sunil Verma identifies how he makes treatment decisions for his patients, noting that he tends to use endocrine treatments instead of chemotherapy.
Video Categories: Breast Cancer and ESMO